Ultragenyx Pharma (RARE) Rating Maintained

The company have set target price per share of $62.0 on Ultragenyx Pharma (RARE) shares. This is 34.52 % from the last stock close price. In an analyst report issued to clients on Tuesday morning, Barclays reconfirmed their “Equal Weight” rating on shares of RARE.

Out of 15 brokers covering Ultragenyx Pharma, 0 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $125 and the lowest is $66 according to Thomson/First Call. The 12-month mean target is $96.4, which means upside potential of ∞% over the current price.

Institutional Ownership

Iguana Healthcare Management Llc had the biggest stake with ownership of 200,000 shares as of q2 2015 for 5.07% of the stocks portfolio. Weatherbie Capital Llc is another notably bullish active investment manager who is possessing 230,628 shares of Ultragenyx Pharma or 2.06% of their stocks portfolio. Also, Opaleye Management Inc. have 1.3% of their stocks portfolio invested in the company for 35,000 shares. The Illinois-based fund Columbia Wanger Asset Management Llc revealed it had acquired a stake worth about 1.17% of the active investment manager’s stock portfolio in Ultragenyx Pharma. The Pennsylvania-based fund Emerald Mutual Fund Advisers Trust is also positive about the stock, possessing 1.26 million shares or 0.96% of their stocks portfolio.

Ultragenyx Pharma (RARE) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Ultragenyx Pharma has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.

Get the latest Ultragenyx Pharma (RARE) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Barclays Analyst Reaffirmed $62.0 Price Target on Ultragenyx Pharma (RARE) stock, While Reiterating “Equal Weight” Rating appeared first on Octafinance.